In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Big Pharma Licensing Trends

Executive Summary

Big pharma comprises a smaller proportion of the deals market than mid-size and smaller biopharmas or biotechs, but it is the biggest spender. A free audio/video excerpt on big pharma licensing trends from Datamonitor Healthcare's webinar, "From R&D Investment To Externalization: Where Is The Pharma Industry Maximizing Value?"

Externalization is an important part of big pharma's business model. It is a key growth strategy that complements the investments these companies make in internal research & development. Big pharmas use deal-making to augment their pipelines and portfolios (through in-licensing), and conversely, to monetize non-core assets or to take advantage of unique external capabilities (through out-licensing).

Based on a review of licensing trends from 2012–16, big pharma companies have produced a significant amount of deals across various phases and therapy areas, with a high concentration at the early stages of development, and in oncology.

On May 23, Datamonitor Healthcare presented a webinar "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" Click below for the audio/video deep dive into big pharma licensing trends between 2012 and 2016.

Big Pharma Licensing Trends

Datamonitor Healthcare

For more information about Datamonitor Healthcare, click here.

Advertisement

Related Content

Big Pharma Licensing Growth Slows In 2016

Topics

Advertisement
UsernamePublicRestriction

Register

IV005134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel